About Us

Chief Executive Officer – Co founder

Pierre is a serial entrepreneur with more than 30 years’ experience in the biopharmaceutical industry. He co-founded Enterome and has led the company since its inception in 2012. Prior to Enterome, Pierre held various C-level positions from commercial operations to business development and M&A at Sanofi ophthalmology, Ethypharm and UroGene (the latter was acquired by Pierre Fabre in 2004). Pierre also founded Fovea Pharmaceuticals, a company acquired by Sanofi in 2009. Pierre also serves as Director on the Board of Iltoo Pharma.

Pierre holds a PharmD from Grenoble Faculty of Medicine and Pharmacy, a PhD from University Pierre and Marie Curie and an MBA from INSEAD.

Chief Corporate Officer – Co founder

Marie-Laure has 20 years’ experience in business management and development in the biopharmaceutical industry. Marie-Laure co-founded Enterome and has led corporate operations since then. Previously, she served as Business Development & Contract Manager at Sanofi and held business development positions at UroGene and Fovea Pharmaceuticals (the latter was sold to Sanofi in 2009).

Marie-Laure holds a Master’s degree in economics from Université Lyon 2.

Chief Financial Officer

Christelle has more than 20 years’ experience in senior finance roles from various industries including 10 years in the pharmaceutical industry at Fournier/Solvay Pharma. She joined Enterome in 2015 from Laboratoire Hepatoum-Dermophil Indien where she served as General Secretary. Prior to that, she led the finance department at Almavia and Polygon/Munters France-Belgium.

Christelle holds a Master’s degree in business management from the ISC Paris.

Chief Medical Officer

Jan has more than 30 years’ experience in immuno-oncology. He joined Enterome in 2019 after an extensive career in industry and academia. Jan worked for 10 years at the Karolinska Hospital before becoming a therapeutic Area Expert (Oncology) at Roche for many years. He was also the CMO at Micromet (including being Vice President Global Development at Amgen after Amgen’s acquisition of Micromet). In addition, he worked as the CMO of both ISA Pharmaceuticals and SOTIO.

Jan holds an MD and PhD. from the Karolinska Institute.

Chief Business Officer

William has over a decade of industry experience in strategic advisory and corporate development, with numerous successful transactions. William is also a biotech co-founder, bringing Enterome a blend of financial acumen and entrepreneurial spirit. Fluently speaking four languages, William holds an MSc in Business Administration as well as an MSc in International Management from Rennes University.

Chief Executive Officer – Co founder

Pierre is a serial entrepreneur with more than 30 years’ experience in the biopharmaceutical industry. He co-founded Enterome and has led the company since its inception in 2012. Prior to Enterome, Pierre held various C-level positions from commercial operations to business development and M&A at Sanofi ophthalmology, Ethypharm and UroGene (the latter was acquired by Pierre Fabre in 2004). Pierre also founded Fovea Pharmaceuticals, a company acquired by Sanofi in 2009. Pierre also serves as director on the Board of Iltoo Pharma.

Pierre holds a PharmD from Grenoble Faculty of Medicine and Pharmacy, a PhD from University Pierre and Marie Curie and an MBA from INSEAD.

Director / Seventure Partners

Isabelle has served as a member of Enterome’s Board since 2008. CEO and Managing Partner of Seventure Partners where she launched Health for Life Capital™, the first European investment vehicle to support the microbiome revolution. Isabelle leads the lifesciences team and personally invests in biotech, nutrition & healthcare. Prior to joining Seventure in 2001, she managed multiple international deals at Pfizer and Fournier/Abbott at Business Development positions and began her career in 1991 with Arthur Andersen in Detroit, USA. Isabelle also serves as director on the Board of Limm Therapeutics,Ysopia, TargEDys, Polaris and Maat Pharma SA.

Isabelle has a degree in Engineering from French Ecole Centrale Paris and holds DECF and ISEB degrees.

Director / Lundbeckfonden BioCapital

Lars has more than 15 years of experience in the life-science industry. He joined Enterome’s board in 2021. Lars is currently a Senior Principal at Lundbeckfonden BioCapital, which he joined in 2021. Prior to Lundbeckfonden BioCapital, Lars worked in business development at MedImmune / AstraZeneca in Cambridge UK. In this position he was responsible for establishing research and development collaborations and licensing around oncology technology platforms. Lars also worked in life science investing at the Wellcome Trust in London, business development in the biotech industry in Oxford, and as a consultant for the Boston Consulting Group (BCG) in Copenhagen. He has previously been a board member of Acesion Pharma in Copenhagen and Canbex Therapeutics in London.

Lars holds a master’s degree in biochemistry from the University of Copenhagen, a PhD. from Heidelberg University and EMBL in Heidelberg, and has a business master’s, MPhil, from Cambridge University.

Director / Primo Capital

Michele has been appointed to the Board of Directors as a representative of Primo Capital. With over 25 years of experience in the financial sector, Michele has held executive roles in various financial and industrial companies across Europe. He has successfully originated, negotiated, and executed deals both as a Principal and on behalf of private and institutional investors. His career includes positions at Société Générale Investment Bank and Credit Suisse. He later served as Managing Director and CEO for asset management and financial advisory firms across Europe. Michele was a Board Member of Banco BPM, Italy’s third-largest banking group, and currently sits on the Board of Directors at Banca Akros. Additionally, he is an Adjunct Professor of Corporate Finance at the Catholic University in Milan.

Michele holds an MBA from HEC Paris and an MPhil in Economics from EHESS/Ecole Normale (now Paris School of Economics). He began his career as an economist and econometrician at the OECD.

Chairman of the Board

Peter Hirth has joined Enterome’s Board in 2023, bringing 30 years of biotech leadership and expertise in the biopharmaceutical industry. He cofounded and led Plexxikon up to its acquisition by Daiichi Sankyo in 2011. He also was cofounder and president of Sugen, acquired by Pharmacia/Pfizer. He currently serves as IO Biotech’s Chairman and holds directorial roles at Vaxcyte, Trex Bio, and Aligos Therapeutics. He’s also an Advisor to Wellington Partners. Dr. Hirth started his career as a researcher with the Max Planck Institutes. after receiving his PhD in Molecular Genetics from Heidelberg University and completing his post-doctoral work at the University of California, San Diego.

Chief Medical Officer / IFLI

Spearheading collaborative research and innovation in hematology, driving impactful therapeutic advancements as Chief Medical Officer. Expertise spans drug development, science-driven investment, clinical trials, and strategic analysis, reinforced through board-level contributions and a proven commitment to transforming patient outcomes.
Venture investments by identifying and evaluating new breakthrough science in collaboration with multiple life sciences funds and partners.

Previous leadership roles at Deciphera Pharmaceuticals, Kyowa Kirin, IQVIA, Sanofi and Amgen emphasized drug strategy and clinical development. Extensive experience in R&D and clinical research reflects a career mission to align scientific breakthroughs with strategic objectives. Dedicated to fostering innovation and shaping the future of oncology and hematology therapeutics.